Form 8K WAVE LIFE SCIENCES For: 18 November By Investing.com
This article reports that WAVE LIFE SCIENCES filed a Form 8K on November 18, 2026. The filing is brief and does not provide further details within the visible content, indicating it is likely a standard regulatory disclosure.
Wave Life Sciences shareholders approve equity plan amendment and board re-elections
Wave Life Sciences, Inc. (NASDAQ:WVE) shareholders approved an amendment to the company's 2021 Equity Incentive Plan, increasing available shares for equity awards by 11,000,000. Additionally, nine directors were re-elected to the board to serve until the 2027 annual meeting, and KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026. A non-binding advisory vote on executive compensation also passed.
An investment adviser reports a 0% stake in Wave Life Sciences (WVE).
Maverick Capital, an investment adviser, along with Maverick Capital Management, LLC, and Lee S. Ainslie III, reported beneficial ownership of 0 ordinary shares, or 0.0% of Wave Life Sciences (WVE) as of September 30, 2026. This information was disclosed in an amended SCHEDULE 13G/A filing with the SEC. The filing clarifies the roles of the reporting entities and individuals in relation to their investment discretion.
Wave Life Sciences Highlights WVE-007 (INHBE siRNA) Progress at ObesityWeek® 2026
Wave Life Sciences is highlighting the progress of its investigational drug WVE-007 (INHBE siRNA) at ObesityWeek® 2026, emphasizing its novel mechanism for inducing fat loss without muscle loss and supporting once- or twice-yearly dosing. The company shared positive Phase 1 data showing durable Activin E reductions and improvements in body composition, especially in individuals with higher BMI and adiposity. Wave is also advancing a Phase 2a monotherapy trial and a combination trial with tirzepatide, with six-month data from the monotherapy trial expected in 2027.
After one dose, a fat-related signal fell by up to 88% on average. Wave expects obesity-trial data in 2027.
Wave Life Sciences presented updated data for its WVE-007 obesity trial at ObesityWeek 2026, highlighting significant reductions in Activin E and improvements in body composition without muscle loss. In Phase 1, single doses led to durable reductions in visceral fat and waist circumference, particularly in cohorts with higher baseline BMI. The company is advancing a Phase 2a monotherapy trial with data expected in 2027, and has initiated a Phase 2a combination trial with tirzepatide, planning to integrate maintenance testing to accelerate data availability.
Wave Life Sciences to Present at Jefferies Global Healthcare Conference in London
Wave Life Sciences, a clinical-stage biotechnology company, announced that its President and CEO, Paul Bolno, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 18, 2026. A live webcast of the presentation will be available on the company's investor relations website, with a replay archived for a limited time. The company is focused on RNA medicines for rare and common disorders, with lead programs in obesity, alpha-1 antitrypsin deficiency, and PNPLA3 I148M liver disease.
Wave Life Sciences stock outlines WVE-008 path after Research Day
Wave Life Sciences plans to file a clinical trial application for WVE-008 in genetically defined liver disease during the fourth quarter of 2026, following positive preclinical findings. The company also highlighted WVE-007 and WVE-006 as its next key clinical milestones, with data from ongoing trials expected later in 2026. This announcement came after its Research Day, where the company detailed the path forward for its RNA-editing candidates.
Wave Life Sciences stock trades at EUR 3.18 before Research Day
Wave Life Sciences stock was trading at EUR 3.18 on Tuesday, November 3, 2026, ahead of its scheduled virtual Research Day on Wednesday, November 4. The company is set to present new platform data focusing on its RNA medicines, which utilize editing, splicing, RNA interference, and antisense silencing. Lead programs target obesity, alpha-1 antitrypsin deficiency, and PNPLA3 I148M liver disease, with investors keen on updates clarifying development priorities.
Leerink Partners Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $10
Leerink Partners has reiterated its Buy rating on Wave Life Sciences (WVE.US), keeping its target price at $10. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Wave Life Sciences Ltd. (WVE) Seasonal returns chart
This article from Yahoo Finance presents a seasonal returns chart for Wave Life Sciences Ltd. (WVE), showing the average monthly price return from 2016 to 2026. It includes current stock performance and mentions the company's recent Q3 2026 earnings call.
Wave Life Sciences stock trades at EUR 3.27: Q3 revenue reaches USD 13.16 million
Wave Life Sciences reported Q3 2026 revenue of USD 13.16 million, exceeding analyst estimates, despite a net loss of USD 61.91 million. The company's stock is trading near its yearly low, but a Research Day scheduled for November 4, 2026, and a recent "Buy" rating from UBS with an USD 11.00 price target provide potential catalysts. Increased R&D spending highlights the company's focus on its RNA medicines pipeline.
RBC Capital Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $15
RBC Capital has reaffirmed its Buy rating for Wave Life Sciences (WVE.US) and maintained its target price at $15. This indicates continued confidence from the firm in the company's prospects.
UBS Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $11
UBS has reiterated its Buy rating for Wave Life Sciences (WVE.US) and maintained its target price at $11. This indicates continued confidence from the firm in the company's future performance.
Oppenheimer cuts Wave Life Sciences stock price target on model update
Oppenheimer has reduced its price target for Wave Life Sciences (NASDAQ:WVE) shares from $32 to $29, while maintaining an Outperform rating, following the company's third-quarter 2026 results and business update. Despite the stock's significant year-to-date decline of 79%, InvestingPro analysis suggests it is undervalued. The company plans a single two-year registrational trial for WVE-006 and expects to release 600mg data for both WVE-006 and WVE-007 later in the fourth quarter.
Oppenheimer cuts Wave Life Sciences stock price target on model update
Oppenheimer has reduced its price target for Wave Life Sciences (NASDAQ: WVE) from $32 to $29, while maintaining an Outperform rating, following the company's Q3 2026 results and business updates. Despite the stock being down 79% year-to-date and trading significantly below its 52-week high, Oppenheimer still views it as undervalued. The company announced plans for a single two-year registrational trial for WVE-006, with a one-year interim analysis for potential accelerated approval, and also reported better-than-expected Q3 2026 revenue of $13.16 million, largely due to collaboration income from GlaxoSmithKline.
Wave Life Sciences (WVE) Stock Rallies While Q3 Results Deepen Loss Concerns
Wave Life Sciences (WVE) saw its stock jump 7.5% despite its Q3 2026 report showing a deepened net loss of US$61.9m, or US$0.30 per share. While short-term traders reacted positively to the rally, longer-term investors are evaluating the company's recurring losses and high sales multiples against its clinical ambitions. The article highlights both the optimism surrounding Wave's RNA editing platform and concerns about funding strain and pipeline risk given modest collaboration revenue and a widening twelve-month deficit.
Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
Wave Life Sciences (Nasdaq: WVE) announced its third-quarter 2026 financial results and provided a business update. The company is advancing its lead clinical programs, including WVE-006 for AATD with plans for a registrational trial, WVE-007 for obesity across multiple treatment settings, and WVE-008 for PNPLA3 liver disease. Wave also reported strong financial positioning with $431.0 million in cash and expects a cash runway into Q3 2028, bolstered by a $12 million milestone payment from GSK.
Wave Life Sciences Ltd earnings beat by $0.02, revenue topped estimates
Wave Life Sciences Ltd (NASDAQ: WVE) reported a Q3 EPS of $-0.300, surpassing analyst estimates by $0.02, and revenue of $13.16M, significantly exceeding the consensus of $7.24M. Despite the strong earnings beat, the company's stock price has declined over the last 3 and 12 months, with its financial health rated as "fair performance" by InvestingPro.
Wave Life Sciences Ltd earnings beat by $0.02, revenue topped estimates
Wave Life Sciences Ltd (NASDAQ: WVE) reported a third-quarter EPS of $-0.300, which beat analyst estimates by $0.02. The company also exceeded revenue expectations, bringing in $13.16M against a consensus estimate of $7.24M. Despite the earnings beat, the stock has seen significant declines over the last 3 and 12 months.
Wave Life Sciences Ltd earnings beat by $0.02, revenue topped estimates
Wave Life Sciences Ltd (NASDAQ: WVE) reported third-quarter EPS of $-0.300, surpassing analyst estimates by $0.02, and revenue of $13.16M, significantly exceeding the consensus estimate of $7.24M. Despite the strong earnings beat, the company's stock price has experienced significant declines over the past three and twelve months. InvestingPro rates Wave Life Sciences Ltd's financial health as "fair performance."
Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
Wave Life Sciences announced its third-quarter 2026 financial results, highlighting significant progress in its clinical programs for AATD (WVE-006), obesity (WVE-007), and PNPLA3 liver disease (WVE-008). The company also reported a $12 million milestone payment from GSK for a selected development candidate and expects its cash reserves to fund operations into Q3 2028. An investor conference call and webcast were scheduled to discuss these updates.
$431 million in cash and securities is expected to fund Wave's operations into the third quarter of 2028.
Wave Life Sciences (WVE) reported a wider net loss of $61.9 million in Q3 2026, though revenue increased to $13.2 million. The company is advancing several clinical programs, including WVE-006 for AATD and WVE-007 for obesity, with key milestones expected in Q4 2026. Wave's cash, cash equivalents, and marketable securities totaled $431.0 million, projected to fund operations into Q3 2028.
Wave Life Sciences (WVE) Stock Rallies While Q3 Results Deepen Loss Concerns
Wave Life Sciences (WVE) stock saw a 7.5% jump following its Q3 2026 report, despite the results showing a deepening net loss of US$61.9m. While the company's RNA editing ambitions are highlighted by optimistic investors, skeptics remain concerned about recurring losses, rich sales multiples, and potential funding strain if strategic partnerships or milestones are delayed. The wider trailing 12-month net loss of US$210.53m underscores the challenge of achieving profitability and the dependence on future clinical readouts and deals.
WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path
WAVE Life Sciences discussed progress in its obesity-focused siRNA program and RNA editing pipeline for alpha-1 antitrypsin deficiency (AATD). The company presented Phase I data for WVE-007, showing reductions in fat while preserving lean muscle mass, and highlighted FDA alignment on an innovative trial design for its AATD RNA editing program aimed at shortening the approval path. WAVE plans further studies, including combination therapies for WVE-007 and discussions on next-generation chemistry.
Wave sets Research Day for November 4: Wave Life Sciences stock is valued at USD 624.6 million
Wave Life Sciences has scheduled a virtual Research Day for November 4, 2026, to present new data on its RNA medicines platform and pipeline updates for various diseases. This event follows recent FDA feedback supporting a two-year trial for its WVE-006 program and the initiation of a Phase 2a combination trial for obesity. The company, with a market capitalization of USD 624.6 million, aims to balance clinical progress with financial results, given its second-quarter revenue of USD 2.27 million fell short of expectations.
Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026
Wave Life Sciences (Nasdaq: WVE) will host a live webcast and conference call on Tuesday, October 27, 2026, at 8:30 a.m. ET to discuss its third-quarter 2026 financial results and provide business updates. The event will be accessible via the "Investor Events" section of the company's website, with an archived version available afterward. The biotechnology company, focused on RNA medicines, will provide insights into its PRISM® platform and pipeline, which includes programs for obesity, alpha-1 antitrypsin deficiency, and PNPLA3 I148M liver disease, among others.
Wave Life Sciences at Chardan’s 10th Annual Healthcare Conference: chemistry focus
Wave Life Sciences presented at Chardan's 10th Annual Healthcare Conference, detailing updates on its RNA medicine pipeline for obesity and liver disease, emphasizing its chemistry platform as a key differentiator. The company highlighted encouraging early clinical data for its lead siRNA program, WVE-007, showing significant fat reduction in a Phase I study, and discussed regulatory alignment for its Alpha-1 antitrypsin deficiency editing program. Management stressed that its proprietary modifications enhance AGO2 loading, potentially allowing for deeper, longer-lasting dosing and extending RNA medicines beyond liver targets.
Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026
Wave Life Sciences, Inc. (Nasdaq: WVE) will host a live webcast and conference call on Tuesday, October 27, 2026, at 8:30 a.m. ET to discuss its third quarter 2026 financial results and provide business updates. The company, a clinical-stage biotechnology firm, focuses on RNA medicines and will make an archived version of the webcast available on its website after the event.
A live webcast will review Wave Life Sciences' third-quarter results on Oct. 27.
Wave Life Sciences (WVE) will host a live webcast and conference call on Tuesday, October 27, 2026, at 8:30 a.m. ET to discuss its third-quarter 2026 financial results and provide business updates. An archived version of the webcast will be available on the company's website following the event. The company's PRISM® platform and pipeline are focused on various RNA medicine modalities and programs, including obesity and Duchenne muscular dystrophy.
Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026
Wave Life Sciences, a clinical-stage biotechnology company, announced it will host a virtual Research Day on November 4, 2026, to showcase new data from its RNA medicines platform. The event will feature insights from a leading hepatologist on PNPLA3 I148M liver disease and the potential of RNA editing. An archived webcast will be available following the live event.
Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026
Wave Life Sciences (Nasdaq: WVE) will host a virtual Research Day on November 4, 2026, at 9:30 a.m. ET to showcase new data from its RNA medicines platform, including its chemistry, hepatic and extra-hepatic capabilities, and RNAi, RNA editing, and bifunctional modalities. The event will also feature Dr. Arun J. Sanyal, a leading hepatologist, who will discuss PNPLA3 I148M liver disease and the potential of RNA editing for its correction. A webcast of the event will be available on the company's investor relations website.
New data on medicines that act on genetic messages is coming Nov. 4 from Wave Life Sciences
Wave Life Sciences (WVE) will host a virtual Research Day on November 4, 2026, to share new data on its RNA medicines platform, including RNA interference, RNA editing, and bifunctional approaches. The event will also feature hepatologist Arun J. Sanyal discussing PNPLA3 I148M liver disease and the potential for RNA editing correction. A webcast will be available on Wave’s investor relations website.
Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026
Wave Life Sciences (Nasdaq: WVE) will host a virtual Research Day on November 4, 2026, to present new data on its RNA medicines platform, including chemistry, hepatic and extra-hepatic capabilities, and various RNA modalities. The event will also feature Dr. Arun J. Sanyal discussing PNPLA3 I148M liver disease and RNA editing correction. A webcast will be available on the company's investor relations website.
Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026
Wave Life Sciences, Inc. (Nasdaq: WVE) announced it will host a virtual Research Day on Wednesday, November 4, 2026, at 9:30 a.m. ET. The event will showcase new data on its RNA medicines platform, including chemistry innovations and various modalities like RNAi and RNA editing. The Research Day will also feature Dr. Arun J. Sanyal, a leading hepatologist, discussing PNPLA3 I148M liver disease and potential RNA editing approaches.
William Blair initiates Wave Life Sciences stock with outperform rating By Investing.com
William Blair has initiated coverage on Wave Life Sciences (NASDAQ: WVE) with an Outperform rating and a DCF-adjusted valuation of $8.37. The clinical-stage RNA medicines company is currently trading near its 52-week low, and William Blair projects significant sales for its WVE-006 and WVE-007 programs by 2036. The company also recently reported Q2 2026 financial results that missed expectations, but it holds a strong cash position and has received FDA alignment for a pivotal study for WVE-006.
William Blair initiates Wave Life Sciences stock with outperform rating
William Blair has initiated coverage on Wave Life Sciences (NASDAQ:WVE) with an Outperform rating and a DCF-adjusted valuation of $8.37. The company's stock currently trades at $3.19, appearing undervalued, and it holds more cash than debt. Wave Life Sciences is advancing WVE-006 for alpha-1 antitrypsin deficiency and WVE-007 for obesity, with significant sales projections for both programs by 2036.
Wave Life Sciences (WVE) Stock Fair Value Moves Lower As Analysts Cut Growth Views
Wave Life Sciences (WVE) has seen its modeled fair value reduced from US$19.63 to US$17.68, a 10% cut, due to analysts lowering growth views and concerns over execution risk and a more focused pipeline. While some firms like William Blair and UBS remain bullish on programs like WVE-006 and WVE-007, others like JPMorgan, Clear Street, Citi, and Mizuho express caution, citing the need for more convincing data and concerns about program concentration. This re-evaluation has also led to adjustments in expected revenue growth, profit margins, and the discount rate in the valuation model.
William Blair Initiates Wave Life Sciences(WVE.US) With Buy Rating, Announces Target Price $8.37
William Blair has initiated coverage on Wave Life Sciences (WVE.US) with a Buy rating. The firm has also set a target price of $8.37 for the company's stock. This new rating and price target indicate a positive outlook from William Blair on Wave Life Sciences' future performance.
Wave Life Sciences Price Target Announced at $11.00/Share by UBS
UBS has set a price target of $11.00 per share for Wave Life Sciences (NASDAQ:WVE). This new target suggests a potential upside for the company's stock. The announcement comes after a recent analysis by UBS.
William Blair initiates Wave Life Sciences stock with outperform rating By Investing.com
William Blair has initiated coverage on Wave Life Sciences (NASDAQ:WVE) with an Outperform rating, setting a DCF-adjusted valuation of $8.37, significantly higher than its current trading price of $3.19. The company, a clinical-stage RNA medicines firm, is advancing two key drug candidates, WVE-006 and WVE-007, for alpha-1 antitrypsin deficiency and obesity, respectively. William Blair projects substantial future sales for both drugs, while acknowledging risks such as clinical setbacks, competition, and regulatory hurdles.
UBS Initiates Wave Life Sciences at Buy With $11 Price Target
UBS has initiated coverage on Wave Life Sciences (WVE) with a Buy rating and set an $11 price target. This initiation suggests a positive outlook from UBS on the company's prospects.
Wave Life Sciences, Inc. SEC Filing (Oct 14, 2026)
This article reports on an ARS SEC filing by Wave Life Sciences, Inc. (WVE) on October 14, 2026. The filing was accepted by the SEC EDGAR system at 05:16 PM EDT on the same day. The report also includes recent news and SEC filings related to Wave Life Sciences, providing an overview of the company's activities and stock data.
Wave Life Sciences to Present at Chardan’s 10th Annual Healthcare Conference
Wave Life Sciences, Inc. announced that its President and CEO, Paul Bolno, MD, MBA, will participate in a panel at Chardan's 10th Annual Healthcare Conference on October 20, 2026. The panel, "RNA Medicines: Next-Generation RNA Therapeutics," will feature discussions on the company's focus on RNA medicines and its PRISM® platform. A live webcast and archived replay will be available through the company's investor relations website.
Wave Life Sciences to Present at Chardan's 10th Annual Healthcare Conference
Wave Life Sciences (Nasdaq: WVE) announced that its President and CEO, Paul Bolno, MD, MBA, is scheduled to participate in a panel discussion at Chardan's 10th Annual Healthcare Conference on October 20, 2026, to discuss RNA medicines. The company, a clinical-stage biotechnology firm, focuses on RNA medicines and has a pipeline targeting obesity, alpha-1 antitrypsin deficiency, PNPLA3 I148M liver disease, Duchenne muscular dystrophy, and Huntington's disease. A live webcast of the panel will be available on the company's investor relations website.
Wave Life Sciences to Present at Chardan’s 10th Annual Healthcare Conference
Wave Life Sciences announced that its President and CEO, Paul Bolno, MD, MBA, will participate in a panel discussion at Chardan’s 10th Annual Healthcare Conference on October 20, 2026. The panel, "RNA Medicines: Next-Generation RNA Therapeutics," will feature insights into the company's focus on RNA medicines for various disorders. A live webcast and replay of the event will be available on the company's investor relations website.
A biotech CEO is scheduled to discuss medicines that use RNA in New York on Oct. 20.
Wave Life Sciences (WVE) announced that its President and CEO, Paul Bolno, will participate in Chardan's 10th Annual Healthcare Conference on October 20, 2026. He will join a panel discussion titled "RNA Medicines: Next-Generation RNA Therapeutics" in New York City. A live webcast of the panel will be available on the company's website, with a replay accessible for a limited period.
We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully
Wave Life Sciences (NASDAQ:WVE) currently has a cash runway of about 2.5 years, based on its US$491m cash reserves and US$193m annual cash burn. While the company reduced its cash burn by 3.5% in the last year, a 30% revenue dip is a concern. The article suggests that while the cash runway is decent, the company should carefully consider the potential cost and dilution if it needs to raise more money in the future.
Form 4 Wave Life Sciences For: 10 October By Investing.com
This article from Investing.com is a regulatory filing update, announcing the Form 4 for Wave Life Sciences for the date of October 10. It appears to be a brief, informational notice rather than a detailed news report, likely indicating a change in ownership or beneficial interest in the company.
Here's Why We're Watching Wave Life Sciences' (NASDAQ:WVE) Cash Burn Situation
This article examines Wave Life Sciences' (NASDAQ:WVE) cash burn rate, noting its significant operating losses and comparing its cash reserves to these losses. It suggests that while the company has a substantial cash runway currently, its high burn rate necessitates careful monitoring of its financial health and future funding needs. The analysis highlights that Wave Life Sciences is spending approximately 25% of its market cap each year, indicating potential dilution if future capital raises are required.
Form 4 Wave Life Sciences For: 10 October By Investing.com
This article from Investing.com reports on a Form 4 filing for Wave Life Sciences (WVE) on October 10. Form 4s disclose changes in beneficial ownership of company stock by insiders. The article provides no specific details from the filing itself, serving primarily as a notification of its existence.